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 ii 
Our goal is to understand mechanisms by which estrogen can influence brain function and cognition.  
Cholinergic projections have a significant impact on neuronal plasticity and cognition in the brain. Estrogen 
has been shown to influence neuronal plasticity as well, and this effect can be mediated by the cholinergic 
system.  Recent studies suggest that local estrogen synthesis, which is regulated by many neurotransmitters 
and hormones, can have a greater impact on neuronal survival and plasticity than systemic estrogen 
administration. One possible way for the cholinergic system to influence estrogen functions in the brain is 
through the regulation of local estrogen production. In this project, we hypothesize that cholinergic inputs can 
regulate aromatase (ARO) expression and activity in specific regions of the adult brain, leading to 
neuroprotection and increase synaptic plasticity. To test this hypothesis, a RT-PCR assay was developed to 
quantify ARO mRNA; and a microsomal incubation method was established to test ARO activity.  First we 
tested the effects of ovariectomy and estrogen or G1 (a GPR30 agonist) treatments on ARO mRNA and 
activity in different brain regions.  This was important because subsequent experiments would be conducted 
using ovariectomized rats. The second goal was to test the effects of removing cholinergic inputs on ARO in 
the hippocampus. Selective cholinergic lesions were performed, yet there was no effect of lesions on either 
ARO mRNA or activity in the hippocampus. The third goal was to test the effect of cholinesterase inhibitor 
(ChEI) treatments on ARO in different brain regions. Two ChEIs--Donepezil and Galantamine--which are 
used in treating Alzheimer’s dementia were used. ChEI treatments changed neither ARO mRNA level nor 
activity in the hippocampus or frontal cortex. Hence, our results suggest that cholinergic system do not 
regulate ARO in these regions of the brain. This suggests that the regulation of local estrogen production is not 
a mechanism by which cholinergic inputs regulate neural plasticity in these regions. However, ChEIs did 
increase ARO activity in the amygdala, which is a region that is important for anxiety and emotion. Hence it is 
possible that cholinergic inputs may regulate emotional function in the amygdala through aromatase.  
 iii 
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1.0  INTRODUCTION 
1.1 THE BENEFIT AND RISK OF ESTROGEN REPLACEMENT THERARY  
Neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease, 
become an increasing concern for 21st century as the life span become longer than before. With 
age, there is a risk of cognitive function decline. We are interested in searching for the factors 
that cause the loss of learning and memory functions in old people.  Particularly, post-
menopausal women, accompanied by the decreasing estrogen level, are more vulnerable to 
cognitive decline. Many efforts have been made to prevent and protect women from loss of 
memory, wherein the effect of estrogen on cognitive function is considered to play a very 
important role.   
Preclinical research suggests that estrogen has beneficial effects on cognitive functions. 
Systemic estrogen treatment significantly improved the performance of ovariectomized (OVX) 
rats in different cognitive tasks, such as: T-maze, radial maze task, visual object recognition and 
novel object placement task [1-5], which were used to test different types of memory. Human 
studies also showed beneficial effects of estrogen on specific cognitive tasks, that related to 
verbal memory and executive functions in younger surgically menopausal or premenopausal 
women [6].Estrogen was shown to help prevent the progression of Alzheimer’s disease. Several 
papers reported that estrogen increased cerebral blood flow [7, 8] and reduced atrophy in the 
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hippocampus and cortex associated with aging and Alzheimer’s disease (AD) [9, 10]. Clinical 
research has also reported that estrogen significantly reduce the memory decline in Benton 
Visual Retention Test (BVRT), a measure of short-term visual memory, visual perception, and 
constructional skills[11] and the risk of developing Alzheimer’s disease (AD)-related dementia 
[12].  
Estrogen affects brain functions by binding and activating estrogen receptors (ER). 
There are two nuclear estrogen receptors (ERs), ERα and ERβ [13]，activation of which can 
regulate gene transcription but are also capable of activating second messenger signaling 
pathways such as mitogen-activated protein kinases (MAPK), calcium/calmodulin-dependent 
protein kinases (CamKII), and cAMP response element-binding proteins (CREB) [14, 15]. 
Recently, a novel membrane-associated estrogen receptor was identified, GPR30, which belongs 
to the seven-transmembrane-spanning G protein coupled receptor family, was identified [16-18]. 
It is located both intracellularly and on the plasma membranes and promotes a rapid estrogen 
signaling in a variety of cell types. In the rat brain, GPR30 exists in many regions, including the 
cortex, hippocampus and hypothalamus [17, 19]. Studies from our lab and others reported that 
GPR30 plays a very important role in mediating estrogen effects in the brain [20, 21].  
           Although systemic estrogen treatment was shown to be beneficial to cognition, people are 
concerned about its side effects. In addition to some common side effects, such as headaches, 
nausea, weight gain etc., estrogen replacement treatment (ERT) also increases the risk of stroke 
and cancers. In 2002, Women’s Health Initiative (WHI) published a large study, which involved 
more than 16,000 healthy women, showed that the combination of estrogen and progestin 
increased the risk of breast cancer, heart disease, stroke, and blood clots. Although the study 
concluded that using estrogen alone has no increasing risk of breast cancer or heart disease, it did 
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appear to increase the risk of stroke. Since then, the use of HRT to relieve menopause symptoms 
has been sharply decreased. An alternative to ERT for the benefit of cognitive function is 
urgently needed. 
1.2 BASAL FOREBRAIN CHOLINERGIC SYSTEM IS IMPORTANT FOR 
LEARNING AND MEMORY 
Research in our lab suggests that the beneficial effect of estrogen on learning and memory 
may mediate through the cholinergic system pathway. Evidence showed that estrogen treatment 
enhances the cholinergic system function by increasing choline acetyltransferase (ChAT) [22-
26], high affinity choline uptake in the hippocampus and frontal cortex [27], and potassium-
stimulated acetylcholine (ACh) release [28, 29].  Selective cholinergic lesion in the medial 
septum, which reduced the ACh projections to the hippocampus, also blocked the effect of 
estrogen on spatial learning in a delayed matching-to-position (DMP) T-maze task [30]. On the 
contrary, giving acetylcholinesterase inhibitors partially restored estradiol (E2) effects on 
learning in aged rats [31, 32], and in young rats with partial cholinergic lesions [33]. These 
findings suggest that basal forebrain system is required for estrogen to influence cognition. 
The basal forebrain cholinergic system is defined as the projection of cholinergic neurons 
from the medial septum (MS), diagonal band of Broca (DBB), and nucleus basalis 
magnocellularis (NBM) to the hippocampus and cerebral cortex. It was first recognized to play 
an important role in the regulation of learning and memory 40 years ago, where the cholinergic 
synapses were modified as a result of learning [34]. Administration of anti-muscarinic agents, 
such as atropine and scopolamine, as well as anti-nicotinic drugs, such as mecamylamine were 
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shown to impair the cognitive performance of rodents in many paradigms, such as spatial 
learning task, passive avoidance procedures and operant tasks [35-37]. Cholinergic lesions in the 
basal forebrain, which decreased cholinergic projections to the cortex and hippocampus, also 
showed the damage effect on those tasks [35]. In primates and humans, the damage of the basal 
forebrain system is also associated with memory deficits. These factors suggest that the basal 
forebrain cholinergic system is necessary for learning and memory.   
Studies also indicate that the impairment of the basal forebrain cholinergic system is 
associated with the dementia symptom in Alzheimer’s disease. The progressive loss of 
cholinergic neurons was shown in Alzheimer’s disease patients and was accompanied by the 
reduction of cholinergic markers, such as choline acetyltransferase (ChAT) and high affinity 
choline transporter -- a rate limiting protein for acetylcholine production [38].A reduction of 
M1,M2-muscarinic receptors in the hippocampus and nicotinic cholinergic receptor in the cortex  
appeared in the transgenic Tg2576 mouse, a mouse model to mimic the production of β-
amyloid, which is a pathological feature in AD patients [39].  β-amyloid can also inhibit choline 
uptake and decrease endogenous acetylcholine release without influence on ChAT activity under 
acute conditions in the hippocampus [40]. As a result, therapies to enhance cholinergic system 
functions, such as administration of acetylcholine precursor and the cholinesterase inhibitor 
(ChEI: Donepezil, Galantamine, Rivastigmine et al), which would decrease the degradation of 
acetylcholine, are employed to slow down the memory decline in AD patients. 
             Cholinergic projections are also important for regulating neuronal plasticity. For 
example, acetylcholine is involved in experience-dependent visual cortex plasticity at the level of 
synaptic transmission [41]. Muscarinic receptors are involved in, and specifically activation of 
the M1 receptor contributes to modifications of neural circuitry [42]. Evidence suggests that the 
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signal transduction cascade of the cholinergic pathway may act synergistically with the 
glutamate pathway through NMDA receptor , whose activation is required for cortical plasticity 
[41].In addition, several studies indicate that the cholinergic system mediates the effect of 
estrogen on cognition and plasticity. For example, administration of the acetylcholine muscarinic 
receptor antagonist, scopolamine, is able to block estrogenic enhancement of water maze task 
[43]. Destruction of cholinergic neurons in the medial septum prevented E2-mediated induction 
of dendritic spines on CA1 pyramidal cells [44] and reduced E2-mediated disinhibition of CA1 
pyramidal cells [45]. Acetylcholine also mediates the E2 induced increase in NMDA binding in 
region CA1 of the hippocampus [43]. Since the manipulation of the cholinergic system 
influenced the effect of E2 on cognition and plasticity, we started to explore mechanisms to 
explain these results. The focus of my work is on one possible way for the cholinergic system to 
mediate estrogen function by regulating aromatase and local production of estrogen.  
 
1.3 THE FUNCTION AND REGULATION OF AROMATASE IN THE BRAIN 
1.3.1  Aromatase is important for neuroprotection and the regulation of neural plasticity 
          As systemic estrogen treatment cannot improve learning and memory without severe side 
effects, local estrogen production in the brain has been increasingly drawing attention of 
scientists these days. Brain aromatase (ARO), which is composed of CYP19A1 and NADPH, is 
the enzyme that irreversibly converts androgen (both androstenedione and testosterone) to 
estrogen (estrone and estradiol) respectively [46]. In previous studies, the research of ARO 
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mainly focused on its function to regulate sexual dimorphism [47], as the highest ARO mRNA 
and activity were found in the preoptic area, medial amygdala and the bed nucleus of stria 
terminalis, which are important region for regulating sexual behavior. Recent evidence suggests 
that ARO also exists in other brain regions--such as the hippocampus, cortex--where it shows 
significant effects on neuronal survival, plasticity, and functionality in adult mammals. As a 
cytochrome P450 enzyme, the majority of ARO is in the microsome, whereas several papers 
showed that ARO immunoreactivity was also found in pre-synaptic axon vesicles in the zebra 
finch or other vertebrate brain, which made the local estradiol production work as 
neurotransmitter possible [48]. Also, ARO has been reported to be co-localized within brain 
regions that contain estrogen receptors (ERs). It is possible that the locally produced estrogen 
exerts its biological effects by binding to these intracellular ERs [49].  
Several studies indicate that ARO plays important roles in neuroprotection.  Evidence 
showed that different stress conditions, such as serum deprivation or addition of glutamate to the 
cultures, can enhance ARO expression in hippocampal astrocytes in vitro [50]. In vivo, ARO 
expression and activity also increased in several experimental disease models, such as brain 
injury [51], experimental stroke [52], spontaneously hypertension [53] and neuroinflammation 
[54]. In addition, ARO can protect the neuronal death induced by neurotoxin. Studies showed 
that ARO significantly protects neuronal loss in the hippocampus induced by domoic acid and 
kanic acid, which are well characterized neurotoxins for hilar neurons in rats. These effects can 
be blocked by an intracerebral injection of fadrozole, an ARO inhibitor, which indicates that the 
local cerebral ARO activity is involved in the neuroprotection [55]. Several studies also suggest 
that the change of ARO level in the brain is relevant to Alzheimer’s disease (AD). Carbo et all 
showed that genetic variation of single-nucleotide polymorphism CYP19 was associated with the 
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earlier onset of AD [56]. Another group also found that two haplotype blocks in CYP19 
increased the risk of developing Alzheimer’s disease by two fold in APOE4 carriers [57]. In 
addition, decreased ARO expression was reported in the hippocampus of AD patients [58]. 
Inducing ARO and local E2 production was showed to protect hippocampal neurons from beta 
amyloid toxicity [59]. This evidence suggests that ARO is important to protect brain functions 
and prevent neurodegeneration. 
Brain ARO also shows the effect on the regulation of brain plasticity, which is a possible 
mechanism to explain its role on cognition. Indirect evidence showed that both testosterone 
propionate and dehydroepiandrosterone (DHEA) increased the density of spine synapses on 
pyramidal neurons in the CA1 area of the hippocampus of ovariectomized (OVX) adult female 
rats. This can be completely blocked by letrozole, a powerful nonsteroidal ARO inhibitor [60]. In 
addition, ARO inhibition reduced axon outgrowth in the neonatal hippocampal cell cultures [61]. 
Evidence also showed that active ARO was expressed by radial glial cells, one of the neural 
progenitor cells in several species including rodents and birds [62-64] and IP cells during cortical 
neurogenesis in vitro. The same was also found in the adult teleost and zebra finch brains [65-
68]. These findings suggest that brain ARO is important to regulate neuronal plasticity  
This collectively suggests that like cholinergic projections, local E2 production in brain 
mediated by ARO can have powerful effects on neuronal protection.  One possibility is that these 
events are connected, that the effects of cholinergic inputs in the brain are mediated via 
regulating the expression and activity of aromatase. 
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1.3.2  Regulation of aromatase 
There are two ways to regulate brain aromatase (ARO). One way is through the 
regulation of ARO gene expression by multiple neurotransmitters and neurosteroids. The ARO 
gene locates on the long arm of chromosome 9. It spans 2863bp length, with 613-2124bp is the 
coding region contains 9 exons (2-10). Upstream are several alternative 5’-untranslated first 
exons resulting from the use of different promoters that are tissue specific [69].Promoter I.f has 
been found to regulate the production of specific brain ARO. Previous study showed that some 
substances, such as progesterone and the glucocorticoid, dexamethasone regulate the expression 
of brain ARO by binding to the specific region of promoter I.f [70, 71]. Some steroid hormones 
were also reported to regulate ARO through transcription level, although whether it was through 
the specific brain promoter I.f was still unknown. Androgens, such as testosterone and 
dihydrotestosterone (which was non-aromatasable) were shown to have a binding site on ARO 
gene to regulate its transcription and stability in a gender specific and region specific manner 
[72-74]. Except for the specific brain promoter I.f for ARO, other studies, which used a highly 
sensitive ribonuclease protection assay, demonstrated that there were two different length ARO 
fragments in the rat brain regions. One was 430nt length, which was associated with enzyme 
activity in the brain, the other was 300nt shorter, whose function was unknown and seemed to be 
brain specific. Different brain regions have different combinations of those two gene types, 
which made the study of ARO more complex [73].  
 Another possible way to influence ARO function is through the regulation of ARO 
activity. One possible mechanism is to rapidly change ARO activity though the regulation in 
post-transcription level. Studies done by Dr J Balthazart illustrated that in neural tissue of male 
Japanese quail, the presence of Mg2+, Ca2+ and ATP in hypothalamic homogenates and the 
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exposure to high Ca2+ level following a K+-induced depolarization in brain can rapidly down-
regulate the local ARO activity. This was achieved by increasing the intercellular Ca2+ 
concentration to enhance the phosphorylation of ARO [75-78]. Several neurotransmitters, such 
as glutamatergic, catecholamine (including dopamine, noradrenaline) were proposed to regulate 
ARO activity in this way as they were known to regulate adenylyl cyclase activity and cyclic 
AMP concentration[79].  
There are two kinds of acetylcholine receptor: muscarinic and nicotinic receptors. 
Muscarinic receptors are receptors belonging to G-protein-coupled receptors; the activation of 
them may trigger a second message cascade, which will deactivate adenylate cyclase and activate 
the K+ channel to hyperpolarize the cell. Nicotinic receptors are ligand-gated ion channels, 
binding with acetylcholine will trigger the diffusion of Na+ and K+ in to the cell and cause 
depolarization. Activation of both receptors will lead to the change of internal Ca2+ level, which 
makes the cholinergic system regulation of ARO possible. 
1.4 OVERVIEW OF THESIS  
 The purpose of this project is to test whether the cholinergic system regulates aromatase 
(ARO) expression and activity in the brain, which if true, may provide a possible mechanism by 
which the cholinergic system mediates estrogen’s function on learning and memory. We 
hypothesize that cholinergic inputs can regulate ARO expression and activity in specific regions 
of adult rat brain, leading to neuroprotection and increased synaptic plasticity. Specific goals 
were as follows: 1) test the effects of ovariectomy (OVX), E2 and G1 on ARO mRNA and 
activity in specific regions of the brain, 2) test the effects of selective septal cholinergic lesions 
 9 
on ARO mRNA and activity in the hippocampus, 3) test the effects of systemic injection of 
cholinesterase inhibitor (ChEI) on ARO expression and activity in the hippocampus, frontal 
cortex, amygdala and preoptic area. These goals will be described in greater detail in the 
following chapters.    
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2.0  METHOD DEVELOPMENT 
Overview: In this project, we hypothesize that cholinergic inputs can regulate aromatase (ARO) 
expression and activity in specific regions of the adult brain. To measure changes in the levels of 
ARO mRNA, we performed quantitative real time reverse transcription PCR (q-RT-PCR). As 
part of our studies, this method was validated to have a wide detectable range, high specificity 
and reproducibility.  To test the changes in ARO activity, we first tried to use a radiometric assay 
described in the literature, which measures the production of tritiated water following 
aromatization of [3H]androstenedione.  This method was found to lack sufficient sensitivity to 
reliably detect ARO activity in adult brain tissues. Therefore, we developed a microsomal 
incubation method, which involves isolating microsomes and measuring the conversion of 
testosterone to estradiol using LC-MS-MS. This method was validated to be sensitive and 
reproducible. Details of these methods are described below: 
2.1  qRT-PCR METHOD FOR COMPARING RELATIVE LEVELS OF 
AROMATASE mRNA: 
2.1.1  Description of q-RT-PCR method 
Collection of tissues, extraction of mRNA and preparation of cDNA:  
 11 
        Animals were anesthetized using a mixture of 0.6mg xylazine and 3mg ketamine (overdose).  
Brains were removed and tissues from the hippocampus, frontal cortex, preoptic area, and 
amygdala were dissected.  Each piece of tissue was sonicated in 1mL Trizol (Invitrogen, Inc.)  at 
4 ℃. The homogenate was mixed with an equal volume of chloroform and centrifuged at 
12,000xg.  The supernatant was collected and isopropyl alcohol was added to precipitate nucleic 
acids. Nucleic acids were pelleted by centrifugation, and the pellet was dissolved in DEPC water 
for 10 min at 42℃. DNA residues were then digested by adding DNA seI (10U/µl) and 
incubating for 10 minutes. The remaining RNA was re-extracted with phenol-chloroform and 
precipitated with sodium acetate and ETOH. The concentration of RNA was determined by 
spectrophotometry using a Nanodrop 2000 (Thermo Scientific). mRNA was then reverse 
transcribed to cDNA using the SuperScript III kit (Invitrogen, Inc.) as per manufacturer’s 
recommendations. RNase H was used to denature any residual mRNA.  
 
qPCR Method: 
2µl of cDNA, 10µl of SYBR Green, and 1.2µl primer pair was pipetted to each well of a 96 
plate (0.1mL/well). The primer pairs used for aromatase were: ARO primer paire 1: sense: 5’-
GCTTCTCATCGCAGAGTATCCGG-3’; antisense: 5’-
CAAGGGTAAATTCATTGGGCTTGG-3’.  ARO primer pair 2: sense: 5’-
CGTCATGTTGCTTCTCATCG-3’; anti-sense: 5’-TACCGCAGGCTCTCGTTAAT-3’. 
GAPDH was used as the control gene:  GAPDH sense: 5’-TGCCACTCAGAAGACTGTGG-3’. 
GAPDH antisense:  5’-GGATGCAGGGATGATGTTCT-3’.  The product of ARO primer 1 is 
290bp length, whereas the product of ARO primer pair 2 is 150bp length. Both of the products 
are located in coding region of the ARO gene within exons 8 and 9. These primer pairs were 
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validated by Genebank primer-BLAST.  Ultimately we chose to use ARO primer pair 2 since the 
resulting cycle number for amplification obtained with this primer pair was more consistent than 
with primer pair 1. The product of the GAPDH primer is 85bp length and is located on exon 6 of 
the GAPDH gene. 
PCR was conducted using the 7300 Sequence Detection System (ABI), with an initial step 
at 50 ℃ for 2 min，95 ℃ for 10 mins and 15 s,  then 40 cycles of 60 ℃ for 1 min. At the end of 
the amplification, samples were set to 95℃ for 15s， 60 ℃ for 30s,  and 95℃ for15s to obtain 
the melt curve.  Data were analyzed using Sequence Detection System (SDS) software (ABI, 
Inc.), and results were obtained as Ct (threshold cycle number) values. The effects of treatment 
on relative ARO mRNA levels were calculated using the following formula: 
 
  
 
ANOVA evaluating the effects of treatment on Ct values for GAPDH did not detect any 
significant effects on Ct (p=0.721>0.05). This suggests that treatments had no significant effect 
on relative levels of GAPDH mRNA. All ratio values were normalized to the mean of vehicle 
treated controls. ANOVA was used to analyze the differences between group means. Tukey HSD 
was used to determine significant differences in expression between treatment groups and 
control.  
 
 
Where E = the efficiency of the PCR reaction defined as 10-1/slope 
of a serial dilution curve, which showed a liner relation between 
cDNA concentration and Ct number.ΔCt is the mean difference in 
Ct for treatment vs control (from Pfaffl) 
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2.1.2   Validation of q-RT-PCR method 
         Product validation: To verify whether the ARO primer pairs we designed amplify a product 
of the expected size, we ran the product on an agarose gel. 1µl 100bp DNA ladder mixed with 
2µl 6x Gel Loading buffer was loaded in one lane and was used to identify the size of the 
product. As the result shows in Figure1 (A), the product of ARO primer pair 1 is approximately 
250bp length and the product of ARO primer pair 2 is approximately 150bp length as predicted. 
No other bands from these two primer pairs were detected, which suggests that these primer pairs 
for ARO specifically amplify the ARO sequences as predicted. 
           Positive control: To test whether the ARO primer pair we designed was able to detect the 
change of ARO mRNA expression after drug treatment, we obtained the mRNA extracted from 
cultured rat ovarian granulosa cells (kindly provided by Dr. Anthony Zeleznik). Two groups of 
granulosa cells were used. One group was treated with follicle stimulating hormone (FSH), 
which is known to increase ARO mRNA expression in the granulosa cells. A second group was 
not treated with FSH and was used as a control. We used our PCR method to measure the change 
in ARO mRNA level between these two groups. Data were normalized to levels of GAPDH 
mRNA. Result in Table1 shows that with the FSH treatment, the ΔCt of ARO mRNA was 10 
times less using cDNA obtained from the FSH-treated cells than for cDNA obtained from the un-
treated cells.  This suggests that levels of ARO mRNA were 210 - fold higher in FSH-treated cells 
than in untreated cells, and indicates that our method is able to detect a large change in ARO 
mRNA expression in these cells. 
          Linear range: To find out the linear range of q-RT-PCR method, we did a serial dilution of 
the cDNA sample and used GAPDH or ARO primer pairs to test the cycle number change. 
Figure 1(B) and (C) show that there are linear relationship between dilution and cycle number in 
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the range of 17 to 34 cycles for GAPDH and 24 to 32 cycles for ARO, which suggest that q-RT-
PCR method is able to quantify changes in relative levels of ARO mRNA under 32 cycle number. 
          Reproducibility: We also tested the reproducibility of q-RT-PCR method by calculating 
the coefficient of variation of both ARO and GAPDH. To do this, identical samples were 
analyzed in different wells of the plate. This experiment was repeated and the coefficient of 
variation (CV) was calculated for each run and each primer pair. Both the CV for GAPDH and 
ARO primer pairs were less than 2% for each time, which suggests that the method has good 
reproducibility. 
       
     
 
Figure 1: The validation of q-RT-PCR method: (A) Agarose gel illustrates the size of DNA products produced 
by PCR amplification using two ARO primer pairs and one primer pair for GAPDH. (B) Dilution curve 
showing change in Ct for detection of GAPDH mRNA. (C) Dilution curve showing the change in Ct for 
detection of ARO mRNA.  
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  -FSH +FSH 
GAPDH 17.8741 18.9585 
Aromatase 29.3444 20.7128 
 
Table 1:  Ct number for aromatase and GAPDH obtained from granulosa cells with and without FSH treatment. 
2.2 METHODS FOR MEASURING AROMATASE ACTIVITY 
Overview: Two methods for measuring aromatase (ARO) activity in brain tissues were 
developed and tested.  One method is referred to as the tritiated water method.  The other is 
referred to as the microsomal incubation method.  Both methods are based on the ability of ARO 
to convert androgens (testosterone and androstenedione) to estrogens (estradiol and estrone). The 
tritiated water assay is well described and is the assay most commonly used in the literature for 
measuring ARO activity.  In this assay, tritiated androstendione serves as the substrate, and 
activity is quantified by measuring the production of tritiated water.  The reaction is as follow:         
[3H] androstendione                                                                       Estrone + [3H] H2O 
For the microsomal incubation method, a microsomal fraction is prepared from the tissues. 
Testosterone serves as the substrate and enzyme activity is quantified by measured the 
production of estradiol using LC-MS-MS. The reaction is as follow: 
Testosterone                                                                           Estradiol + H2O 
Aromatase + NADPH 
Aromatase + NADPH 
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2.2.1 Aromatase assay 
i. 3H-Water Method 
This method was first described by Rossile (1991). Hippocampal tissue (approximately 
80mg) was sonicated in buffer I (pH7.4), which contained 10mM Potassium phosphate, 100mM 
potassium chloride, 1mM DTT, and 1mM EDTA. 100µl of tissue sonicate was used as one point. 
40pmol androstenediol (AD) mixture was prepared containing both [3H]1β-AD (24.0 
Ci/mmol)and cold AD (24 µM) to yield 700,000 cpm for each reaction. To begin the reaction, 
20µl of 10mg/mL NADPH was added to each incubation tube. Tubes were capped, vortexed and 
placed into a water bath at 37℃ for one to four hours. For incubation time longer than1 hour, an 
additional 2.0 µl of 100mg/mL NADPH stock was added every 1 hour. To terminate the 
reaction, 400 µl ice cold 10% trichloroacetic acid containing 2% activated charcoal was added to 
each tube, vortexed and placed on ice. After that, the reaction tubes were centrifuged at 1200xg 
for 15min and the supernatants were filtered through AFDX-50 columns. These columns were 
then washed with 600µl ddH2O three times and effluents were collected in 200mL scintillation 
vials. Scintisafe scintillation fluid (Fisher Scientific) was added and the amount of tritium was 
determined using an LKB beta-counter. The total cpm included in each reaction also was tested 
without filtering through the column. Reference samples were included and included all 
components listed above with the exception of the tissue sample. The value of 3H20 was 
calculated by the average of triplicate samples subtracting the reference and normalized to the 
protein concentration. The protein concentration was determined by a Bovine Serum Albumin 
(BSA) standard curve (0.2-1.4mg/mL) using DC protein assay kit (Bio-Rad). Each standard and 
unknown was analyzed in triplicate. ARO activity is reported as cpm/h/µg protein. 
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            ii. Limitations of this assay 
Column: It was necessary to determine the appropriate length of the column for filtering 
each sample after completing the reaction. Specifically, the column length needed to be 
sufficient to remove the non-reacted [3H]AD without retaining much of the 3H2O. As the column 
was hand-made, it was difficult to obtain a consistent column length.  Also, the way in which 
samples were loaded onto the columns appeared to be critical.  It appeared to be important that 
all of the samples went through the center of the column and through the resin so as not to pass 
between the resin and the side of the column. This would affect the efficiency with which 
[3H]AD was retained.  These technical issues added variability to the results which affected 
sensitivity (see below).   
Sensitivity: Another limitation of the method was poor sensitivity and high background, 
resulting in the need to obtain large amounts of tissue to increase total activity.  As part of our 
validation we compared ARO activity in ovarian tissue vs. hippocampal tissue. For ovarian 
tissue, ARO activity was high and activity was easy to detect. In contrast, we were not able to 
reliably detect ARO activity in hippocampal tissue, even when combining tissues from three 
animals (~500 mg).  We concluded that this method would not be sensitive enough to measure 
changes in ARO activity in the adult brain and so proceeded to develop and validate an 
alternative method. 
2.2.2 Microsomal incubation method  
Due to the limitation of the tritiated water assay, we tried to develop a more sensitive and 
reproducible method to detect aromatase (ARO) activity. As estradiol is lipophilic, there is 
possibility that cytoplasmic membranes may sequester or trap some produced estradiol, which 
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makes the free estradiol undetectable.   Based on that assumption, we extracted microsomes from 
tissues, incubated with testosterone, and used LC-MS-MS method to detect the production of 
estradiol. The LC-MS-MS method had been previous validated for measuring estradiol in serum 
was shown to be 1 pg/mL with reliable detection at 2.5 pg/mL.  
i. Method  
Microsome extraction: Tissues (200-300mg) were combined together and homogenized 
in 50mM Tris Buffer (pH 7.4) containing 150mM KCl, 0.1mM Dithiothreitol, 1mM EDTA and 
20%Glycerol, and mixed with 0.113mM Butylated Hydroxytoluene (BHT) and  0.100mM 
Phenylmethylsulfonylflouride (PMSF) prior to the experiment at 4℃. After homogenization, 
we balanced the weight of the sample containing ultracentrifuge tubes and did the first spin at 
90,000g for 33mins at 4℃ using the Ti70 rotor to get rid of the large cellular particles. After that, 
the supernatant was centrifuged at 240,000g to get the microsomal pellet. The microsomal pellets 
were then dissolved in 200µl 0.25M sucrose solution.  
Protein assay: We used Bradford protein assay to measure the protein concentration of 
each sample. Briefly, Bio-Rad dye reagent was diluted 1:5 with water. 7µl microsomal solution 
was diluted 1:5 with 8% sucrose buffer.  The protein standard solution was prepared by 
dissolving known concentrations of BSA into sucrose buffer. The range of the BSA standard 
curve was 0.1 to 0.5 mg/mL protein. 10µl of each standard solution was pipetted into each well 
of a 96-well plate. Each standard and unknown was analyzed in triplicate. 200µl of diluted dye 
was added to each well, mixed and incubated at room temperature for approximate 15 mins. 
Optical density at 595nm wavelength was determined using an Emax precesion microplate reader 
(Molecular Devices). The concentration of unknown was determined by interpolation of the 
average optical density for the unknown relative to the standard curve. 
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Microsomal incubation assay: To measure ARO activity, microsomes prepared from 
hippocampus, frontal cortex, amygdala, or preoptic area were incubated with testosterone, and 
the amount of estradiol produced was measured by LC-MS-MS. Microsomes were added in to 
the microsomal incubation buffer containing 0.12M Phosphate monobasic, 0.15M Phosphate 
dibasic and 5mM MgCl2.10µl of 40nM testosterone was added to each sample tube to yield a 
final concentration of 400pM Testosterone. To start the reaction, 50µl of 0.02 M NADPH was 
added to each sample, vortexed for 5 sec and then placed at 37℃. After 30 mins, the reaction 
was stopped by rapid cooling on wet ice. 25µl Deuterated E2 (0.5ng/mL) was added to each 
sample and served as an internal standard. 3mL n-butyl chloride was then added and vortexed for 
1 min. The tubes were then centrifuged and the supernatant dried down under a soft steam of 
nitrogen at 37℃ for 20mins. 50µl 50mM Bicarb buffer and 50µl 1mg/ml Dansyl chloride were 
added to each tube and heated at 60℃ for 3 mins to derivatize the estradiol. E2 was eluted using 
a Waters Acquity UPLC BEH C18, 1.7 µm, 2.1 X 150 mm reversed-phase column, with an 
acetonitrile: water (0.1% formic acid) gradient.  MS Detection and quantification were achieved 
in the positive mode.  Transitions used for analysis were 506  171 for E2, and 511  171 for 
the deuterated internal standard. Negative controls included samples that received no 
microsomes or no NADPH. Microsomes from ovarian tissue were used as a positive control. An 
estradiol standard curve also was produced and underwent extraction and derivatization at the 
same time as the unknowns. Known concentrations of E2 in methanol were also measured and 
compared with samples processed as above, to test for effects of the matrix. The amount of 
E2/mL in the unknowns was determined by measuring area under the curve and interpolation 
from the standard curve.  As the volume for unknown sample was twice than the standard 
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solution, we adjusted the unknowns E2 value by dividing by 2. The aromatase activity is 
presented as pg estradiol/h/µg microsome. 
              ii. Validation of the Microsomal Incubation Method: 
            Reproducibility: To test the reproducibility of this method, we ran the same diluted 
ovarian samples six times each day on three different days and calculated the coefficient of 
variation (CV) for each run. According to the result shown in Figure 2(A), the CVs for all runs 
were lower than 10%, suggesting that the method has sufficient reproducibility. We do see a 
trend of decreased estradiol concentration over the three days. One possible explanation for this 
is that the microsomal activity was influenced by the repeated freeze-thaw of the tissue, leading 
to some decrease in enzyme activity.  
             Microsomal concentration curve: To verify whether this method can be used to 
accurately measure differences in ARO activity, a serial dilution curve of microsomes was 
prepared from hippocampal tissue. The range was 75µg - 600µg of microsome per reaction. 
Figure 2(B) shows that there is a linear relationship between microsomal concentration and 
estradiol production, which indicates that this method is able to accurately measure differences in 
ARO activity within this range.  
               Incubation time curve: Next we tested whether ARO activity changes with time during 
the incubation. Activity was measured after 10min, 20min, 30min, 45min, 60min, and 90min 
using microsomes prepared from the same hippocampal tissues. Figure 2(C) shows that there 
were two linear phases for ARO activity. The rate of the reaction was highest during the first 30 
mins with a value of 0.15 pg/h/µg microsome. After that, the rate of the reaction decreased to 
0.03 pg/h/µg microsome, which suggested that enzyme activity had decreased. This may be 
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caused by a limitation of substrate and/or co-factor, by an effect of product formation, or by 
changes to the enzyme itself. An incubation time of 30 mins was used in all future studies.     
       Testosterone concentration curve: Next we evaluated the relationship between substrate 
concentration and product formation, to determine the concentration of the substrate necessary to 
ensure saturating conditions. The substrate concentration curve is shown in Figure 2(D). From 
this curve we calculated that Vmax = 73.7 pg estradiol/h/mg microsome and the Km is 94.71 
nmol/L.  One study reported aromatase activity in the amygdala (Km=30nmol/L, Vmax=79.4 
fmol/h.mg protein) and preoptic area (Km=20nmol/L, Vmax=62.5 fmol/h.mg protein) of adult 
male brain using the tritiated water assay [80]. Dr MaCarthy also used this method and reported 
the value of aromatase activity in the hippocampus（~15 fmol/h.mg protein）, cortex (~11 
fmol/h.mg protein), and hypothalamus(~113fmol/h.mg protein) for new-born rats. In addition, 
she also saw a dramatic fall of brain estradiol level from new born to adult (1.27pg/mg protein to 
~0.1pg/ mg protein), which mainly reflect the brain estradiol production [81]. The value we 
obtained from the microsomal incubation method is hard to compare with the values detected by 
tritiated water assay, as we did not test the total protein concentration we used before microsomal 
extraction. However, with a serial validation, we illustrated that our method is reliable and 
sensitive to detect aromatase activity in the female adult brain. 
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Figure 2: The validation of microsomal incubation method. (A) Graph indicates the reproducibility of this 
method. Bars represent for the estradiol production (pg/h*10µg microsome) using diluted ovarian tissue. The 
coefficient of variation (CV) for each run was lower than 10%, suggesting that the method has sufficient 
reproducibility. (B) Microsomal concentration curve. (C) Incubation time curve. (D) Substrate concentration 
curve 
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Rate 1 = 0.075 pg /h/µg microsome 
Rate 2 = 0.015 pg/h/µg microsome 
Vmax=73.7pg/h/mg microsome 
Km=94.71 nmol/L 
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3.0  EFFECT OF OVARIECTONMY, ESTRADIOL AND G1 ON BRAIN AROMATASE 
EXPRESSION AND ACTIVITY IN DIFFERENT BRAIN REGIONS. 
3.1 OVERVIEW 
Previous studies showed that systemic injection of estradiol (E2) decreased aromatase 
(ARO) expression in the hippocampus, whereas continuous treatment brought about by 
subcutaneous implantation of E2 minipellets increased ARO expression [61]. In our first study, 
we tested the effects of ovariectomy (OVX), E2 and G1 (which is an agonist for GPR30) 
treatments on ARO expression and activity in different regions of the brain using the methods 
described above.  
3.2 EFFECTS OF ESTRADIOL AND G1 ON RELATIVE LEVELS OF 
AROMATASE MRNA IN BRAIN 
3.2.1 Method 
          40 young female Sprague-Dawley rats (10 intact, 30 ovariectomized: OVX) were 
purchased from Hilltop Laboratories, Inc. Rats were ovariectomized by the supplier, shipped, 
and then individually housed in our facility on a 12 hour:12 hour light/dark schedule with 
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unrestricted access to food and water. Rats were housed individually for two weeks before being 
used. Drugs were delivered at a dose of 5 µg/day using miniosmotic pumps (Alzet model 2002) 
implanted under the skin and containing either E2 or G1 dissolved in 20% ß-hydroxypropyl 
cyclodextran and 10% DMSO. These pumps delivered at a continuous rate of 0.5 µL/hour for 14 
days.  Controls received pumps containing vehicle alone.  
On the day of surgery, rats were anesthetized with isoflurane and pumps were implanted 
under the skin on the back. Gonadally intact controls and OVX rats received pumps containing 
vehicle.  Remaining OVX rats received pumps containing E2 or G1. After 7 days of treatment, 
rats were anesthetized with a mixture of 0.6mg xylazine and 3mg ketamine (overdose) and then 
decapitated.  The brains were removed and hippocampus, frontal cortex, amygdala, and preoptic 
area were collected to test ARO mRNA expression using the qRT-PCR methods described 
above. Ratios between ARO and GAPDH were calculated to present the relative mRNA level. 
All ratio values were normalized to the mean of vehicle treated intact controls. ANOVA was 
used to analyze the differences between group means. Tukey HSD was used to determine 
significant differences in expression between treatment groups and control. 
3.2.2  Result 
ΔCt values between Aromatase (ARO) and GAPDH for ovariectomized (OVX) rats  are 
summarized in Table 1. Based on these values, ARO mRNA expression was highest in the 
amygdala, followed by the preoptic area, hippocampus and frontal cortex. This result is in accord 
with previous studies, which has reported that ARO is located in the different brain regions in the 
human, zebra finch and rodent [47, 69].  
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The effect of E2 and G1 on ARO mRNA expression in different brain regions is 
summarized in Figure 3. In OVX rats, mean levels of ARO mRNA were 38% greater in the 
hippocampus and 44% greater in the amygdala compared with intact controls.  In the 
hippocampus, this effect was reversed by continuous E2 or G1 treatment. In contrast, in the 
amygdala, E2 further increased the level of ARO mRNA, whereas G1 had little effect. In the 
frontal cortex and preoptic area, OVX had little effect on mean levels of ARO mRNA expression 
compared with gonadally intact controls. E2 also showed little effect.  In contrast, mean levels 
following G1 treatment were approximately 30% lower than gonadally intact controls in these 
two areas. Most of the differences that we observed were not statistically significant. ANOVA 
revealed no significant effect of treatment on ARO mRNA in the hippocampus (F[7,31]=2.11) , 
frontal cortex(F[7,31]=1.15) and preoptic area(F[7,31]=0.807). In the amygdala, post-hoc 
analysis revealed that E2 significantly increased the relative level of ARO mRNA (p<0.05) 
compared with the intact control. 
3.2.3 Discussion 
            The goal of this experiment was to evaluate the effects of OVX, E2 and G1 treatment on 
relative levels of ARO mRNA in different regions of the brain.  This was done to provide 
information about the effects of OVX and ER agonist treatments in advance of subsequent 
experiments which would be conducted in OVX rats.    
Our results suggest that OVX results in elevated levels of ARO mRNA in the 
hippocampus and amygdala relative to gonadally intact controls. Differences were in the range of 
approximately 30-40%, but were not statistically significant using the current methods. In the 
hippocampus the effect appeared to be reversed by E2 and G1 treatment; whereas, in the 
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amygdala the effect was increased significantly by E2 treatment. This suggests that in the 
hippocampus, OVX increases and estrogen can suppress ARO expression and that the effects 
may be mediated via GPR30. In contrast, in the amygdala, it appears that both OVX and E2 can 
increase ARO mRNA expression, and activation of GPR30 appears to have little effect. The 
results suggest a role for GPR30 as well as other estrogen receptors in regulating ARO 
expression.  The different effects observed in the hippocampus and amygdala may reflect 
differences in the expression of these receptors.  
In the frontal cortex, G1 treatment produced a slight (~30%) decrease in ARO mRNA, 
whereas OVX and E2 treatment had little effect. Similar results were observed for the preoptic 
area.  This suggests that in these regions estrogen has little influence over ARO mRNA 
expression, though there remains some evidence for regulation by GPR30. Note that in all of the 
regions studied, G-1 was associated with a decrease in mean levels of ARO mRNA relative to 
OVX rats, suggesting that activation of GPR30 may have a negative influence on ARO 
expression. 
Reports from other laboratories about the effect of estrogen on aromatase in the brain 
have been inconsistent, and appear to depend on brain region, sex and species. Abdelgadir et al. 
reported that IP injection of 17β -estradiol down-regulates ARO expression, whereas tonic 
estrogen treatment up-regulates ARO expression in the hippocampus[82]. Balthazart reported 
that E2 had no effect on ARO mRNA in the preoptic area and amygdala of castrated male 
mice[83]. Analysis of the ARO gene shows that progesterone, glucocorticoid, and androgens, 
have specific binding sites on ARO gene [70-74], whereas there is no direct regulation site for 
estrogens. It is possible that E2 regulates ARO mRNA expression through the regulation of other 
steroids; however, our data suggest that E2 may influence ARO mRNA expression via GPR30. 
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It is important to note that most of the effects that we observed on relative levels of ARO 
mRNA were not statistically significant. This may be due to limitations in the qRT-PCR methods.  
The delta-delta Ct method is commonly used to quantify changes in relative levels of mRNA in 
tissues, but generally requires effects on the order of 2-fold or greater (i.e., one PCR cycle) to 
achieve statistical significance.  However, many studies show that changes in relative levels of 
mRNA that are less than 2-fold can have some biological significance. Our findings provide 
preliminary data showing that OVX and E2 can influence ARO mRNA expression in a 
regionally specific way, and it is the first to provide some evidence that GPR30 may play a role. 
More sensitive methods, such as Northern blot or solution hybridization studies, could be used to 
further evaluate these findings.  
 
Different brain 
regions 
Hippocampus Frontal Cortex Amygdala Preoptic area 
ΔCt (ARO-
GAPDH 
9.40 10.61 8.14 9.58 
Table 2: Relative level of ARO mRNA in the different brain regions for ovariactomized(OVX) rats. Numbers 
indicate theΔCt between ARO and GAPDH. 
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Figure 3:  Effect of OVX, E2 and G1 on ARO mRNA expression in (A) Hippocampus, (B)Frontal cortex, (C) 
Amygdala and (D) Preoptic regions. Bars indicate the mean ratio of ARO mRNA relative to Intact controls ± 
s.e.m., after normalizing to GAPDH. * indicates the p ≤0.05 compared to control group. N=8 for each group. 
3.3 EFFECT OF ESTRADIOL AND G1 ON AROMATASE ACTIVITY 
3.3.1 Method 
           As a follow-up to our analysis of the effects of OVX, E2 and G-1 on relative levels of 
aromatase (ARO) mRNA, we conducted a preliminary experiment to test the effect of OVX, E2 
and G1 on ARO activity using the microsomal assay described above. 20 OVX rats (n=4 for 
OVX- and G1-treated groups, n=6 for each E2-treated group) were used.  These rats were treated 
with E2 at doses of 1µg/day and 2.5µg/day. Rats were housed in our facility for 1 week before 
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treatment. Different concentrations of E2 (1µg/day, 2.5µg/day) were used to mimic the 
physiological E2 levels of intact rats. 5µg/day of G1 was given to test the effect of activating 
GPR30 on ARO activity. The Alzet model 2002 miniosmotic pumps were used to deliver drugs 
continuously for 7 days. Controls received pumps containing vehicle. Hippocampus, frontal 
cortex, amygdala and preoptic area, were collected as described above. Serum was collected for 
measurement of circulating levels of E2. In order to extract 300µg microsomes from each region, 
we pooled 4 or 6 hippocampi, frontal cortex, amygdala or preoptic area together to get one data 
point for each region. Each bar in the result represented the one pooled sample for each treatment 
group for different brain regions. 
3.3.2 Result 
 The distribution of aromatase (ARO) activity in the different brain regions is 
summarized in Figure 4(A). ARO activity was highest in the amygdala, followed by the preoptic 
area, hippocampus. ARO activity in the frontal cortex was below our ability to detect, despite the 
fact that we did detect ARO mRNA in this region.  
The effect of E2 and G1 on ARO activity in different brain regions is also shown in 
Figure 4. In rats treated with 1µg E2/day ARO activity in the hippocampus was approximately 
40% less than in controls. The effect was not as great in rats treated with 2.5 µg E2/day (~16%), 
but was greater in rats treated with G1 (~60%). In the amygdala, both low and high doses of E2 
seemed to have little effect on ARO activity, whereas the ARO activity was 50% higher in the 
G1-treated group than in controls. In the preoptic area, rats treated with 1 and 2.5 µg E2/day had 
higher levels of ARO activity (>60% in each case) relative to controls, whereas G1 had less of an 
effect (~30%). No ARO activity was detected in the frontal cortex. These data were preliminary 
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as only one data point for each treatment group in each region; however, each data point 
represents a pooled sample, and hence the mean activity in 4-6 rats. 
3.3.3 Discussion 
The goal of this experiment was to collect preliminary data on the effects of OVX and of 
E2 or G1 treatment on aromatase (ARO) activity in different regions of the brain.   
Results showed detection of ARO activity paralleled differences in relative levels of 
ARO mRNA, with highest levels of activity detected in the amygdala, and followed by preoptic 
area and hippocampus. Based on our initial estimates of activity in each region, tissues were 
pooled in order to obtain sufficient microsomes to reliably detect activity in each region.  This 
required combining from 2-4 rats per region.  
For the effect of estrogen on ARO activity, results showed that in the hippocampus, 
levels of ARO activity were less in E2 and G1-treated rats compared with OVX controls. This is 
consistent with the effects on relative levels of ARO mRNA shown above. Together, these 
results suggest that E2 may regulate ARO activity through the regulation of ARO mRNA and 
that this effect may be mediated through GPR30. However, this result must be treated as very 
preliminary since the data represented only one data point per treatment. In addition, with E2 at 
1µg/day, ARO activity decreased more than with E2 treatment at 2.5µg/day, which may suggest 
that there is a dose-related effect of E2 on ARO activity. Further study is needed to confirm this 
effect. 
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In the amygdala, E2 had little effect on ARO activity, whereas G1 increased ARO 
activity by 50% compared with OVX control. The lack of effect of E2 on ARO activity was not 
in agreement with the increase in ARO mRNA shown above; however, the effect on ARO 
mRNA was observed using a higher dose of E2 (5 µg/day), which may account for the 
difference. The effect of G1 on ARO activity was, however, consistent with the increase in ARO 
mRNA shown above. This provides further evidence that activation of GPR30 can regulate ARO 
expression and activity. 
In the preoptic area, rats treated with 1.0 and 2.5 µg E2/day had elevated levels of ARO 
activity (~60% greater) relative to controls. G1 had less of an effect (~26% greater). This is in 
contrast to the effects of E2 and G1 on mean level of ARO mRNA shown above.   
As reported above, no ARO activity was detected in the frontal cortex, despite the fact 
that ARO mRNA was readily detectable. This suggests that local estrogen expression is very low 
in this region and may not be biologically relevant. One possibility is that the low level of ARO 
activity reflects the amount of expression for the short version ARO mRNA.  The primers that 
we used for the RT-PCR analysis amplified a region located between exon 9 and 10, and cannot 
distinguish the longer active ARO RNA from the shorter inactive form.  Therefore, it is possible 
that the ARO RNA in the frontal cortex is a non-active form the function of which is unknown. 
Collectively, these data provide preliminary data suggesting that E2 and G1 can influence 
ARO activity in the brain, that the effects are region-specific, and that activation of GPR30 can 
play a role. To our knowledge, this is the first indication that activation of GPR30 can influence 
ARO expression and activity in the brain. 
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Figure 4: Distribution of ARO activity in the different brain regions (A) and effect of OVX, E2 and G1 on 
ARO activity in (B) hippocampus, (C) Amygdala and (D) Preoptic regions. Bars show ARO activity as the rate 
of estradiol production (pg/h/µg microsome) in pooled samples. Each bar represents activity from a pool of 4-6 
samples.  
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4.0  INVESTIGATION OF THE EFFECTS OF SELECTIVE CHOLINERGIC LESION ON 
AROMATASE EXPRESSION AND ACTIVITY IN THE HIPPOCAMPUS  
4.1 OVERVIEW 
Studies showed that estrogens can influence synaptic plasticity in the hippocampus as 
well as performance on specific cognitive tasks. We hypothesized that the cholinergic inputs may 
influence aromatase (ARO) activity in the hippocampus, with corresponding effects on local 
estrogen production. In this experiment, we selectively eliminated cholinergic inputs to the 
hippocampus, and looked for changes in ARO expression and activity. 
4.2 METHOD 
4.2.1 Cholinergic lesion: 
Forty-six, 3 month old Sprague-Dawley (SD) rats were purchased and housed in our 
animal facility for two weeks. 20 rats were used to test for effects on relative levels of ARO 
mRNA.  The other 26 rats were used to test for effects on ARO activity. Rats were anesthetized 
using a mixture of ketamine (36mg/kg) and xylazine (7.2mg/kg), and then placed on a standard 
stereotaxic apparatus. The skull was exposed and a hole was drilled at midline 0.3mm rostral to 
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Bregma. A 28ga stainless steel cannula was lowered -5.6mm from dura to the medial septum 
based on the stereotaxic atlas of Paxinos and Watson (1986). 2.0µl of 192IgG-Saporin (SAP; 
Advanced Targeting Systems, Inc.), which is a selective cholinergic immunotoxin, was injected 
at a rate of 0.2µl /min. Previous studies showed that medial septal SAP injection caused a 
selective loss of cholinergic cells in the basal forebrain with little non-selective damage to 
GABAergic neurons [84].This is also accompanied by decreased activity of choline 
acetyltransferase (ChAT) and by reduced high-affinity uptake of [3H]choline into cholinergic 
nerve terminals in the cerebral cortex and hippocampus [85]. Control group received the same 
amount of saline injection.  The skin was sutured and rats were placed onto a heating patch until 
they woke up. Following surgery, rats received ketofen (3.0 mg/kg) for three days to relieve 
pain. After 14 days of recovery, rats were dissected and the hippocampus and frontal cortex was 
collected and analyzed for ChAT activity, qRT-PCR and ARO activity. Tissues containing the 
medial septum (MS) were fixed by immersion in 4% paraformaldehyde in 50mM phosphate 
buffered saline (PBS, pH7.2) at 4˚C overnight. These tissues were then transferred to 20% 
sucrose in PBS at 4 °C for several days. Sections through the MS were cut and stained for 
ChAT- immunoreactivity as described below. 
4.2.2 ChAT assay 
In order to verify the lesions, we measured ChAT activity in the hippocampus and frontal 
cortex. The expectation was to see a substantial reduction in ChAT activity in the hippocampus 
with little change in ChAT activity in frontal cortex in lesioned rats. Briefly, 30mg tissues were 
sonicated in 300µl medium (10mg tissue/mL) which contains 10mM EDTA and 0.5% Triton X-
100. 10µl of substrate solution, which contains 0.25mM [3H] acetyl-CoA (50,000-60,000 
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dpm/tube), 10.0mM choline chloride, 0.2mM physostigmine sulfate, 300mM NaCl, 50mM 
sodium phosphate buffer(pH 7.4) and 10mM EDTA was added to each reaction tube. 5µl 
(approximately 45mg) aliquots of sample were added to the tubes and incubated for 30 min at 37
℃. Each sample was assayed in triplicate. The reaction was terminated with 4 mL sodium 
phosphate buffer (10mM) at 4℃ in the scintillation well. The production of [3H] acetylcholine 
was detected by adding 1.6 mL of acetonitrile containing 5mg/mL tetrephenylboron followed by 
the addition of 8 mL EconoFluor scintillation cocktail (Packard Instruments, Meriden, CT) and 
counting cpm in the organic phase using an LKB beta-counter. The total cpm in the substrate 
solution was determined by aqueous scintillation cocktail. Background was determined using 
identical tubes with no sample added. Reference was incubated with no sample added. For each 
sample, triplicates were averaged and the difference between cpm in the sample and reference 
was calculated. The final amount of acetylcholine production was normalized to the total cpm in 
the substrate and protein concentration of each sample, which was detected as the average of 
aliquots using Bio-DC assay. ChAT activity was calculated for each sample as pmol 
acetylcholine manufactured/h/µg protein.   
4.2.3 ChAT Immunocytochemistry (ICC) 
To further confirm whether SAP treatment eliminated most of cholinergic neurons in the 
medial septum, we cut sections through the medial septum and stained them for ChAT using 
immunohistochemistry. Briefly, sections were rinsed in 50 mM PBS for one hour and then 
transferred to 0.3% H2O2 in 50 mM PBS for 10 mins. Sections were rinsed again in PBS, and 
then placed in a solution of 50 mM PBS, 5% normal horse serum and 0.05% Triton X-100 
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containing primary antibody against ChAT (goat anti-ChAT 1:3500).  Sections were exposed to 
antibody for three days at 4℃. Then sections were rinsed with PBS for 30 mins and incubated 
with a Biotinylated secondary antibody (horse anti goat 1:220, Vector Laboratories) for 1 hour at 
room temperature. Sections were then rinsed with PBS for another 30 mins and placed in an A/B 
‘Elite’ Horseradish peroxidase solution for 1 h at room temperature. Sections were then rinsed 
with Tris acetate solution (50mM, pH7.6) and transferred to the Tris/DAB solution, which 
contained 0.5 mg/ml 3,3’-diaminobenzidine, 0.01% H2O2 and 0.032% NiCl2 for 10 min. 
Sections were then rinsed with PBS, mounted onto glass slides, dehydrated, coverslipped and 
examined with a Leitz photomicroscope. 
4.2.4 Tissue analysis 
We used q-RT-PCR method to test ARO expression and microsomal incubation assay to 
test ARO activity, as described above. For ARO mRNA, ratios between ARO and GAPDH were 
calculated to present the relative mRNA level. All ratio values were normalized to the mean of 
saline treated OVX controls. ARO activity was presented as pg estradiol production per hour, per 
µg microsomes. ANOVA was used to analyze the differences between group means. Tukey HSD 
was used to determine significant differences in expression between treatment groups and 
control.  
 37 
4.3 RESULTS  
Lesions were evaluated by confirming loss of ChAT-positive cells in the septum, and by 
loss of ChAT activity in the hippocampus. From Figure 5, SAP treatment eliminated most of 
ChAT-positive cells in the medial septum, which indicated a severe loss of cholinergic neurons 
in this region. Accordingly, ChAT activity in the hippocampus was significantly lower (<80%) 
in the lesion treatment group than in the control group (P<0.05). However, the ChAT activity in 
the frontal cortex did not decrease significantly, which was in agreement with results previously 
reported [86]. In the aromatase activity experiment, we did see several partial lesion rats with 
SAP treatment validated by immunohistochemistry, which may be caused by inappropriate 
injection site. As a result, we combined the partial lesion samples together as one group to detect 
aromatase activity. For the effect on aromatase (ARO), relative levels of ARO mRNA were 35% 
higher, and levels of ARO activity were 18.9% higher, in the hippocampus of rats with lesions vs. 
non-lesioned controls (Figure 6). Partial lesion also had little effect on ARO activity. ANOVA 
revealed no significant effect of the treatment on ARO mRNA (F[5,4]=2.635) and  activity 
(F[6,21]=0.287) in the hippocampus. Since the ChAT activity did not change in the frontal 
cortex, this brain region was used as a negative control. The relative level of ARO mRNA did 
not change in this area and the ARO activity in this region was not detected. 
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Figure 5: Effect of Saporin-induced cholinergic lesions in the medial septum on choline acetyltransferase 
(ChAT) activity. Panel A and B shows ChAT immunoreactivity in the medial septum of rats treated with (A) 
Saline and (B) 192-Saporin (SAP). Eleven days following SAP treatment, ChAT activity was evaluated in the 
(C) Frontal Cortex and (D) Hippocampus. After SAP treatment, no significant change in ChAT activity was 
measured in frontal cortex tissue while Hippocampal tissue shows significant reduction in activity. In all 
panels, rostral is toward the top and midline extends top to bottom through the middle of the panel. Scale bar 
=0.5mm.  
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Figure 6: Effect of cholinergic lesion in the medial septum on ARO mRNA expression in (A) Frontal cortex, 
(B) Hippocampus and ARO activity in (C) Hippocampus. No significant change was found in region-specific 
ARO mRNA and activity. Bars in (A) and (B) indicate the mean ratio of ARO mRNA relative to OVX controls 
± s.e.m., after normalizing to GAPDH. Bars in (C) indicate the estradiol production (pg/h*µg microsome) ± 
s.e.m, which represent the ARO activity. 
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4.4 DISCUSSION 
In this experiment, we tested the effect of removing cholinergic afferents on aromatase 
(ARO) mRNA and activity in the hippocampus. Our data suggest that removal of over 90% of 
the cholinergic afferents had a modest effect at best on relative levels of ARO mRNA and ARO 
activity in the hippocampus. Analysis of ChAT activity as well as inspection of the cholinergic 
neurons by immunohistochemistry confirm that the lesions were successful and, therefore, that 
the results were not due to a failure of the lesion surgeries. This suggests that cholinergic inputs 
to the hippocampus do not play a major role in regulating ARO in this region of the brain and 
therefore do not significantly regulate local estrogen production in this region.  As a 
consequence, cholinergic regulation of local estrogen production is not likely to contribute to the 
effects on synaptic plasticity or hippocampal function.   
This result was not our expectation as estrogen was shown to have many effects on 
neuroplasticity and cognition and these were mediated through the cholinergic system. In 
addition, studies have shown increasing the intercellular Ca2+ concentration can enhance the 
phosphorylation of ARO [75-78]. Both m1-m4 and α7 nicotinic receptors are located in the 
hippocampus, whereas α7 is expressed by GABAergic as well as glutamatergic synapses in the 
CA1 stratum radiatum [87], activation of which can change the intercellular Ca2+ level in these 
cells. We anticipated that cholinergic inputs may regulate ARO activity through the regulation of 
internal Ca2+ concentration. However, since our results showed relatively little effect of the 
cholinergic lesions on ARO, we suspect that effects on local estrogen production do not play a 
significant role in cholinergic effects on plasticity in this region.  
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There is another possible explanation for the little effect on ARO observed. Studies have 
shown that SAP lesions of cholinergic neurons are companied by a significant activation of 
microglia and a lesser extent of astrocyte cells in the hippocampus [85]. As has been shown 
before, ARO has neuroprotective function and different stress conditions can induce astrocyte 
ARO expression [51-54]. Study showed that cytokines released by microglia can also trigger the 
expression of ARO in astrocytes [54]. It is possible, therefore, that the cholinergic lesions 
induced ARO expression and activation in astrocytes, which compensated for a down-regulation 
of ARO in neurons of hippocampus. Since our methods do not distinguish ARO in neurons vs. 
astrocytes, we cannot rule out the possibility that cholinergic denervation had significant effects 
on ARO expression in specific cell populations which, collectively, are reflected by relatively 
little change in total ARO activity.  
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5.0  EFFECTS OF CHOLINEASTERASE INHIBITORS ON AROMATASE 
EXPRESSION AND ACTIVITY IN DIFFERENT BRAIN REGIONS. 
5.1 OVERVIEW 
After testing the effect of down-regulating cholinergic input to the hippocampus on 
aromatase (ARO) mRNA expression and activity, we tested the effect of increasing cholinergic 
activity by treating with cholinesterase inhibitors (ChEIs). Two ChEIs: galantamine and 
donepezil, which are employed to slow down memory decline in AD patients, were used to 
inhibit the activity of acetylcholinesterase, which is an enzyme that degrades acetylcholine. We 
then tested the effects of systemic administration of these drugs on ARO expression and activity 
in different brain regions.  
5.2 METHOD 
A total of 48 rats (270-350g) were treated intraperitoneally with 3mg/kg donepezil, 
5mg/kg galantamine or saline (as control) injected once daily for 7days. 12 rats were used to test 
the effect of ChEIs on relative levels of ARO mRNA (4 rats per group), 36 rats were used to test 
effects on ARO activity (12 rats per group). Animals were killed, the brains were removed and 
hippocampus, frontal cortex, amygdala and preoptic area were collected and evaluated for levels 
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of ARO mRNA and ARO activity as described above. For ARO mRNA, ratios between ARO 
and GAPDH were calculated to present the relative mRNA level. All ratio values were 
normalized to the mean of saline treated OVX controls. For ARO activity, tissues were pooled 
(n=2/hippocampus, n=3/frontal cortex, n=3/amygdala, n=4/preoptic area) to get one data point 
for each region. Microsomes were extracted as above, and then incubated with testosterone and 
NADPH for 30 mins. Then the estradiol was extracted as described above and the values were 
determined by comparison with the standard curve. ARO activity was reported as pg estradiol 
production per hour, per µg microsomes. ANOVA was used to analyze the differences between 
group means. Tukey HSD was used to determine significant differences in expression between 
treatment groups and control.  
Donepezil is a piperidine-based highly potent mixed, non-competitive reversible inhibitor 
of acetylcholinesterase, with an in vitro IC50 of approximately 6.7nM and an in vivo ID50 of 
approximately 2.6mg (6.8µMol)/kg brain tissue [88]. Donepezil has a long half-life (~70 hours) 
and is highly bound to albumin [88, 89].  Donepezil is approved for treatment of memory decline 
associated with Alzheimer’s disease.  
Galantamine is a less potent ChEI than donepezil and has a shorter half-life [90], but has 
less binding to serum proteins and a better side-effect profile in humans.  In addition, it has been 
shown to act as an allosteric enhancer at nicotinic receptors [91, 92]. A study by Geerts [93] 
suggests that doses in the range of 1.5-5.0 mg/kg in rats produce optimal brain concentrations for 
the allosteric potentiating ligand effect of galantamine. Like donepezil, galantamine is approved 
for treatment of memory decline associated with Alzheimer’s disease. 
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5.3 RESULT 
Effects of donepezil and galantamine on ARO mRNA and ARO activity are summarized 
in Figure 7. As shown in Figure 7 (A), no significant effects on relative levels of ARO mRNA 
were detected in the hippocampus, frontal cortex, or amygdala of rats treated with ChEIs vs. 
controls. In the POA, however, an increase in ARO mRNA was detected following treatment 
with donepezil (64%) and galantamine (90%, p=0.08).  These effects were not statistically 
significant.  
Figure 7 (B) summarizes effects on ARO activity.  No significant effects of CHEIs 
treatment on ARO activity were detected in the hippocampus or preoptic area, and ARO activity 
in the frontal cortex was undetectable.  In contrast, ARO activity in the amygdala was 30% 
greater in rats treated with donepezil, and 45% greater in rats treated with galantamine, relative 
to controls. The effect of galantamine was statistically significant (p<0.05).  
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Figure 7: Effect of Donepezil and Galantamine on (A) ARO mRNA expression and (B) ARO activity in 
different brain regions of OVX rats. Bars in (A) indicate the mean ratio of ARO mRNA relative to controls ± 
s.e.m., after normalizing to GPADH. Bars in (B) indicate the mean of estradiol production (pg/h* µg 
microsome) ± s.e.m., which represent the ARO activity. HPC: hippocampus. FCT: Frontal cortex. AMG: 
Amygdala. POA: preoptic area. * indicates the p ≤0.05 compared to control group. 
 
5.4 DISCUSSION 
In this experiment, we tested the effect of two ChEIs on ARO expression and activity in 
different regions of the brain. We expected that systemic injection of ChEIs would increase ARO 
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mRNA expression and activity in the hippocampus and frontal cortex. Our result showed that the 
two ChEIs had little influence on ARO expression and activity in most of the brain regions 
examined.  One exception is that both ChEIs appeared to increase levels of ARO mRNA in the 
preoptic area.  Another is that both ChEIs appeared to increase ARO activity in the amygdala.  
These findings suggest that inhibition of cholinesterase, and hence increased cholinergic activity 
can influence ARO expression and activity in a region-specific way; however, there appear to be 
no major effects on ARO expression or activity in the hippocampus or frontal cortex. This 
suggests that the systemic up-regulation of cholinergic activity does not affect the local estrogen 
production in these two regions in OVX rats. This is consistent with the results of our previous 
study which showed that removal of cholinergic inputs did not influence ARO in the 
hippocampus.     
It is unlikely that the negative effect is due to the fact that our drug treatments did not 
work. These two ChEIs have been used in our lab before and reported to significantly inhibit the 
cholinesterase in the brain and caused behavior change [88, 93]. Besides that, we did see an 
increase in chewing behavior for rats with both donepezil and galantamine treatments, indicating 
that our treatment works.  
In contrast, ChEIs did increase ARO activity by approximately 50% in the amygdala 
without changing relative levels of ARO mRNA. This suggests that cholinergic system may 
regulate ARO in a post-transcriptional manner in this region. The amygdala is a central structure 
in limbic circuitry, which is an important system to regulate emotional expression, emotional 
experience and emotional memory, especially fear. It is important for emotional related memory 
formation, consolidation and the use of this memory to make correct response.  It receives many 
cholinergic afferents, which contain large amounts of ACh from basal forebrain cholinergic 
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system as well as inputs from the hippocampus, and this is thought to play a critical role in the 
coordination among different memory systems leading to the selection of appropriate behavioral 
strategies [94]. Study showed that decreasing hippocampal cholinergic signal impaired 
contextual conditioning, whereas increasing cholinergic signal promoted contextual fear 
condition, which highlights the important regulation of cholinergic neurotransmission on 
amygdala functions [95]. Studies also showed that there were α7-nAChRs locating on somatic or 
somato-dendritic regions of basolateral amygdala (BLA) interneurons. These receptors were 
actived in the basal state to enhance GABAergic inhibition [96]. Estradiol is also involved in fear 
recognition and memory in amygdala [97, 98]. Previous study showed that exposure to nicotine 
can increase signs of depression and anxiety in adult female[46]. Based on our result, it is 
possible that cholinergic system from basal forebrain and hippocampus regulates fear learning 
and memory through the regulation of ARO activity in the amygdala. This will require further 
study. 
In the preoptic area, increased levels of ARO mRNA were observed in rats treated with 
donepezil and galantamine; however, the effects were not large and did not reach statistical 
significance.  As discussed above, this may due to limitations of the qRT-PCR method and will 
need to be verified using other more sensitive methods. Nevertheless, our data suggest that 
despite possible increases in ARO mRNA, levels of ARO activity did not change. There are 
several possible explanations.  It is possible that some of the mRNA was degraded before being 
translated into the enzyme, or that the newly translated protein was not stable and was degraded, 
or that treatment increased transcription of the shorter non-active form of ARO.  Further studies 
will be needed to determine which of these possibilities is correct.  
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Collectively, these data provide preliminary data suggesting that manipulation of the 
cholinergic system do not regulate local estrogen production in the hippocampus and frontal 
cortex, which indicates that effects of cholinergic afferents on cell survival and synaptic 
plasticity are not due to cholinergic regulation of local estrogen production. In the amygdala, we 
did see a significant increase in ARO activity after galantamine treatment. This raises the 
possibility that cholinergic inputs may influence local estrogen production in the amygdala, and 
thereby affect amygdala function. To our knowledge, this is the first report of the effect of 
manipulation of the cholinergic system on ARO expression and activity in the brain. 
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6.0  SUMMARY AND CONCLUSIONS 
In this study, we developed and validated a new microsomal incubation method to detect 
aromatase (ARO) activity in rat brain. Before that, there were few studies testing the change of ARO 
activity in the brain using rat models, as the species’ activity tends to be very low, and there is no 
reliable method to detect it. Because of this, Japanese quails, and zebra finches were used to study 
brain ARO due to the relative high levels of local estrogen production. However, there are limitations 
of using birds as study models, as birds cannot mimic humans well, and behavioral studies are not 
often performed on birds. We showed that the microsomal incubation assay was reliable and 
sensitive in detecting rat brain ARO activity, which gave us the chance to study the brain’s local 
estrogen production in a rodent model. 
We have shown that OVX and ER agonist have different effects on aromatases mRNA 
and activity in the different brain regions, although most of the effect were not statistically 
significant. Our findings provide preliminary data showing that OVX and E2 can influence ARO 
in a regionally specific way, and that activation of GPR30 can play a role. To our knowledge, 
this is the first indication that activation of GPR30 can influence ARO expression and activity in 
the brain. This study also raises the question of whether local estrogen production in the brain 
may change in surgically menopausal women, who have lower systemic estrogen levels, which 
could further influence brain functions. 
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For the effect of the cholinergic system on ARO, our results showed that selective 
cholinergic lesions in the medial septum had no effect on ARO mRNA and activity in the 
hippocampus. This suggests that elimination of the basal forebrain cholinergic inputs influence 
neither ARO mRNA level nor activity in this region.  In the hippocampus and frontal cortex, 
donepezil and galantamine had no effects on ARO mRNA expression and activity. This result is 
in accord with the cholinergic lesions experiment and suggests that the manipulation of the 
cholinergic system does not regulate ARO in these two regions. To our knowledge, this is the 
first report of the cholinergic system’s effect on regulating ARO in these regions. Based on these 
data, we concluded that unlike other neurotransmitters, such as glutamate and norepinephrine, 
manipulation of the cholinergic system seemed not to regulate ARO mRNA and activity in these 
regions. This suggests that the effects of cholinergic afferents on cell survival and synaptic 
plasticity in the hippocampus are not due to cholinergic regulation of local estrogen production.    
We showed that galantamine did significantly increase ARO activity level in the 
amygdala, which may suggest that cholinergic input regulates the function of the amygdala, such 
as fear cognition and memory by the regulation of local estrogen production. This study raises 
the possibility that ChEI treatment for Alzheimer’s disease in women might affect emotional 
changes in the patient.  
For future study, since we have shown that GPR30 may mediate E2’s effect on regulating 
ARO mRNA and activity in different brain regions, which provides a possible mechanism for 
systemic estrogen to influence local estrogen production, more study needs to be done to validate 
this effect. Also, the mechanism of why ER agonists act differently in the different brain regions 
need to be investigated. Also, we showed that ChEIs can regulate ARO activity in the amygdala, 
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which may influence emotional function. Further study is needed to test the role of local estrogen 
production on the function of amygdala. 
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